Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Deciphera Pharmaceuticals Inc (Deciphera Pharmaceuticals), a subsidiary of Ono Pharmaceutical Co Ltd, is a commercial-stage biopharmaceutical company to deliver transformational medicines to patients. The company’s pipeline products include ripretinib which treats gastrointestinal stromal tumor; vimseltinib targets tenosynovial giant cell tumor and chronic graft-versus-host disease; tirabrutinib for primary central nervous system lymphoma; sapablursen targets polycythemia vera; ONO-4578 which treats colorectal cancer and nivolumab; ONO-2808 for multiple system atrophy; ONO-2020 treats alzheimer’s disease; DCC-3009 which targets advanced gastrointestinal stromal tumor; inlexisertib for advanced GIST + KIT inhibitor; DCC-2812 treats renal cell carcinoma, urothelial cancer and castration-resistant prostate cancer; and ONO-4685 targets T-cell lymphoma and plaque psoriasis. Deciphera Pharmaceuticals is headquartered in Waltham, Massachusetts, the US.
Headquarters
United States of America
Address
Building B, 200 Smith Street, Waltham, Massachusetts, 02451
Website
www.deciphera.com
Telephone
1 781 2096400
No of Employees
355
Industry
Pharmaceuticals and Healthcare
Revenue (2023)
$163.4M
Deciphera Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Ripretinib: Gastrointestinal Stromal Tumor |
| Vimseltinib: |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In September, the company received approval from the European Commission for ROMVIMZA (vimseltinib) to treat adult patients with symptomatic tenosynovial giant cell tumors. |
| 2024 | Contracts/Agreements | In April, the company signed a merger agreement with ONO Pharmaceutical Co., Ltd. |
| 2024 | Contracts/Agreements | In January, the company entered into an agreement with GENESIS Pharma to commercialize RIPRETINIB in 14 European markets to treat fourth-line gastrointestinal stromal tumors. |
Competitor Comparison
| Key Parameters | Deciphera Pharmaceuticals Inc | Eurofins AvTech Laboratories Inc | BioNTech US Inc | Biothera | Delmont Laboratories Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Waltham | East Lansing | Cambridge | Eagan | Swarthmore |
| State/Province | Massachusetts | Michigan | Massachusetts | Minnesota | Pennsylvania |
| No. of Employees | 355 | - | 71 | - | - |
| Entity Type | Private | Private | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ryota Udagawa | President; Chief Executive Officer | Senior Management | 2024 | - |
| Jenn Larson | Chief Financial Officer; Senior Vice President | Senior Management | 2019 | - |
| Matthew L. Sherman, M.D. | Executive Vice President; Chief Medical Officer | Senior Management | 2019 | - |
| Maria Ostrovsky | General Counsel; Senior Vice President | Senior Management | 2019 | - |
| Lisa Amaya Price | Chief Human Resources Officer; Senior Vice President | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer